查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992822

非專利抗癌藥物市場：2026-2032年全球市場預測（依藥物類型、適應症、通路、給藥途徑、治療階段、作用機制及劑型分類）

Generic Oncology Drugs Market by Drug Type, Indication, Distribution Channel, Route Of Administration, Therapy Line, Mechanism Of Action, Formulation - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年，非專利抗癌藥物市值為415.1億美元，預計到2026年將成長至446.5億美元，年複合成長率為7.13%，到2032年將達到672.5億美元。

主要市場統計數據
基準年 2025 415.1億美元
預計年份：2026年 446.5億美元
預測年份：2032年 672.5億美元
複合年成長率 (%) 7.13%

簡要概述動態的腫瘤學領域，重點關注科學創新、監管壓力和商業性實踐之間的相互作用。

隨著科學進步與不斷變化的監管預期和商業化模式相交融，癌症治療產業正經歷快速變化。本文概述了研發、市場准入和供應鏈韌性等相關人員面臨的關鍵背景，重點關注分子模式創新與在不同醫療環境下為患者提供治療方法的實際考慮之間的相互作用。透過分析近期臨床進展、支付方趨勢和生產實際情況，本文揭示了跨學科規劃為何已成為營運必需而非策略選擇。

科學、監管和商業性因素的融合如何重塑癌症治療的提供方式、對證據的期望以及競爭策略？

腫瘤學領域正從單一療法模式轉變為整合生技藥品、小分子化合物、細胞療法和精準診斷的綜合治療生態系。這一轉變反映了基因組分析、抗體工程和細胞療法等領域技術的成熟，這些技術共同實現了腫瘤生物學更精準的標靶化和抗藥性機制的適應性管理。因此，聯合治療和決策流程正逐漸成為臨床實踐的主流，這需要診斷開發商、製藥公司和醫療服務網路之間更緊密的合作。

評估貿易政策變化對癌症治療供應鏈、籌資策略和製造在地化決策的連鎖反應。

近期影響關稅和跨境關稅的貿易政策發展，為醫藥價值鏈引入了新的變數，尤其對依賴複雜國際供應鏈和專業生產投入的癌症治療領域影響尤為顯著。關稅調整可能增加原料、活性藥物成分和專用包裝材料的到貨成本，進而影響籌資策略和供應商選擇。此外，貿易緊張局勢升級往往會加速生產能力的在地化，促使企業重新評估其在國內或近岸工廠的資本配置，以降低關稅波動和物流延誤帶來的風險。

詳細的細分框架闡明了影響商業策略的各個維度，例如模式、適應症、管道、給藥途徑、治療線、作用機制和製劑。

癌症市場在治療方法、適應症、分銷管道、給藥途徑、治療方案、作用機制和製劑形式方面都呈現出異質性，因此，對細分市場進行清晰的分類對於策略決策至關重要。本分析按藥物類型對市場進行細分，區分生物製劑和小分子藥物，並認知到這些治療方法在研發、生產和監管方面的差異。同時，本分析涵蓋了乳癌、大腸癌、白血病、肺癌、淋巴瘤和前列腺癌等多種適應症，反映了不同癌症患者群體、標準治療背景和臨床實驗室設計要求的差異。

對美洲、歐洲、中東和非洲以及亞太市場的監管、贖回和進入因素進行詳細的區域性分析。

地理差異對於制定有效的策略至關重要，因為區域趨勢會顯著影響監管時間表、報銷框架和患者獲取管道。本分析揭示了美洲地區的獨特模式：不同的支付方模式和生物製藥創新中心與不同的國家採購體系並存，這些因素共同影響定價和分銷選擇。在此背景下，商業化策略必須適應不同的製劑製程和醫師診療模式，同時利用大規模的病患資料集來驗證其價值。

老牌製藥巨頭和靈活的生物技術公司如何調整其產品組合、生產製造和診斷夥伴關係關係，以推動腫瘤領域的創新？

領先的生物製藥公司持續透過對標靶治療、免疫腫瘤學和加速候選化合物發現的平台技術的大量投資，引領著治療方向。它們目前的策略組合兼顧了成熟的化學專長與生技藥品和細胞療法的能力，體現了多重模式策略，該策略降低了研發管線風險，並在各個開發項目之間創造了協同效應。主要企業也正在投資伴隨診斷和數據驅動的患者選擇，以改善臨床療效，並在與支付方進行價格敏感型談判時凸顯其價值提案。

產業領導者整合證據產生、供應彈性、診斷一致性和取得系統的實用策略，助力癌症治療

產業領導者應優先採取切實可行的措施，將科學、商業性和營運方面的努力結合，以保持競爭優勢。首先，他們需要整合實證方案，將隨機對照試驗與真實世界數據策略結合，以支持其對支付方和醫療保健系統的價值主張。這種方法將加強報銷談判，並加速在所有臨床環境中的推廣應用。其次，他們應透過供應商多元化、模組化製造技術和庫存策略來投資供應鏈柔軟性，從而減輕外部衝擊和貿易政策不確定性的影響。

一項綜合性的混合方法研究設計，整合了關鍵相關人員的見解、監管和臨床證據、供應鏈圖譜以及嚴格的檢驗通訊協定。

本研究途徑結合了定性和定量方法，以確保獲得可靠且可重複的見解，從而為決策提供支援。主要研究包括對臨床研究人員、支付方代表、醫院藥局主任和生產負責人進行結構化訪談，以即時了解推廣障礙、採購趨勢和生產限制等方面的觀點。次要研究則利用監管申報文件、同儕審查文獻、臨床實驗室註冊資訊以及公開的衛生監管機構指南，全面檢驗臨床管道、安全性概況和核准先例。

整合關鍵策略挑戰，強調需要進行全面執行、提高供應的適應性以及基於證據的取得。

總之，癌症治療正處於一個轉捩點，商業性敏捷性和營運韌性必須與科學進步保持同步。標靶治療、免疫療法以及先進製劑的成熟為患者提供了新的臨床途徑，但這些機會也帶來了證據生成、生產製造和市場進入日益複雜的挑戰。那些能夠積極協調跨部門資源、整合臨床開發和診斷策略、與支付方合作以及提升供應鏈適應能力的機構，最能將創新轉化為對患者持久的益處。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：非專利抗癌藥物市場：依藥物類型分類

  • 生技藥品
  • 低分子化合物

第9章：非專利抗癌藥物市場：依適應症分類

  • 乳癌
  • 結腸癌
  • 白血病
  • 肺癌
  • 淋巴瘤
  • 攝護腺癌

第10章：非專利抗癌藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：非專利抗癌藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第12章：非專利抗癌藥物市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第13章：非專利抗癌藥物市場：依作用機制分類

  • 化療
  • 免疫療法
    • CAR-T療法
    • 查核點抑制劑
  • 標靶治療
    • 單株抗體
    • 蛋白酪氨酸激酶抑制劑

第14章：非專利抗癌藥物市場：以劑型分類

  • 液體
  • 凍乾粉
  • 藥片

第15章：非專利抗癌藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：非專利抗癌藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：非專利抗癌藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國非專利抗癌藥物市場

第19章：中國非專利抗癌藥物市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accord Healthcare Ltd.
  • Amneal Pharmaceuticals Inc.
  • Aspen Pharmacare Holdings Ltd.
  • Aurobindo Pharma Ltd.
  • Biocon Limited
  • Celltrion Healthcare Co., Ltd.
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Gedeon Richter Plc.
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals Plc
  • Intas Pharmaceuticals Ltd.
  • KRKA dd, Novo mesto
  • Lupin Pharmaceuticals Inc.
  • MSN Laboratories
  • Sandoz Group AG
  • Sawai Pharmaceutical Co., Ltd
  • Shanghai Fosun Pharmaceutical Group Co., Ltd.
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zydus Cadila Healthcare Ltd.
Product Code: MRR-1A1A064C0038

The Generic Oncology Drugs Market was valued at USD 41.51 billion in 2025 and is projected to grow to USD 44.65 billion in 2026, with a CAGR of 7.13%, reaching USD 67.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 41.51 billion
Estimated Year [2026] USD 44.65 billion
Forecast Year [2032] USD 67.25 billion
CAGR (%) 7.13%

A concise orientation to the dynamic oncology therapeutics environment highlighting the interplay of scientific innovation regulatory pressures and commercial execution

The landscape of oncology therapeutics is undergoing rapid realignment as scientific advances intersect with shifting regulatory expectations and evolving commercialization models. This introduction outlines the essential context for stakeholders responsible for research and development, market access, and supply chain resilience, emphasizing the interplay between innovation in molecular modalities and pragmatic considerations for bringing therapies to patients in diverse healthcare settings. By situating recent clinical progress alongside payer dynamics and manufacturing realities, the narrative frames why multi-disciplinary planning has become an operational imperative rather than a strategic luxury.

Transitioning from discovery to durable patient impact requires an appreciation for how scientific promise translates into real-world adoption. Advances in targeted agents and immunotherapies have expanded therapeutic options across tumor types, while novel formulations and administration routes are redefining patient convenience and adherence. At the same time, regulatory pathways are increasingly focused on demonstrating meaningful clinical benefit and safety in broader populations, which underscores the need for robust evidence generation strategies that integrate real-world data and adaptive trial designs. Consequently, decision-makers must balance scientific ambition with pragmatic market readiness to ensure that innovations achieve both regulatory approval and sustainable patient access.

How converging scientific, regulatory, and commercial forces are restructuring oncology care delivery, evidence expectations, and competitive strategies

The oncology landscape has shifted from single-modality paradigms toward integrated therapeutic ecosystems that combine biologics, small molecules, cellular therapies, and precision diagnostics. This transformation reflects technological maturation in areas such as genomic profiling, antibody engineering, and cell-based modalities, which together enable more precise targeting of tumor biology and adaptive management of resistance mechanisms. As a result, clinical practice is moving toward combination regimens and biomarker-driven decision trees that demand closer coordination between diagnostic developers, pharmaceutical sponsors, and care delivery networks.

Alongside scientific change, commercial dynamics are evolving: payers increasingly demand demonstrable value through outcomes-based contracting and tighter scrutiny of comparative effectiveness, while healthcare providers prioritize regimens that reduce institutional burden and outpatient resource utilization. Manufacturing and distribution innovations - including modular biologics production and decentralized fill-finish options - have begun to shift where and how therapies are produced and delivered. Taken together, these trends create opportunities for companies that can integrate R&D agility with resilient supply chains, adaptive pricing strategies, and clear evidence generation plans that resonate with both regulators and payers.

Assessing the ripple effects of shifting trade policy on oncology drug supply chains, procurement strategies, and manufacturing localization decisions

Recent trade policy developments affecting tariffs and cross-border duties have introduced new variables into the pharmaceutical value chain, with particular implications for oncology therapeutics that rely on complex international supply chains and specialized manufacturing inputs. Tariff adjustments can increase landed costs of raw materials, active pharmaceutical ingredients, and specialized packaging components, which in turn influence procurement strategies and supplier selection. In addition, increased trade friction often accelerates efforts to localize manufacturing capacity, prompting firms to reassess capital allocation toward onshore or nearshore facilities to mitigate exposure to tariff volatility and logistical delays.

Beyond cost considerations, tariff changes can prompt strategic shifts in inventory policies and demand forecasting. Stakeholders may lengthen safety stock parameters for critical biologic materials or redesign sourcing networks to diversify supplier geographies. Moreover, regulatory frameworks that incentivize domestic manufacturing - such as procurement preferences or expedited review pathways tied to domestic production - can reshape where companies choose to site advanced manufacturing technologies. Consequently, organizational leaders must integrate tariff risk into scenario planning, evaluate reshoring tradeoffs against scale and expertise, and pursue contractual safeguards with suppliers to maintain continuity of supply for oncology products that are often life-sustaining.

Deep segmentation framework revealing modality, indication, channel, administration, therapy line, mechanism, and formulation dimensions that shape commercial strategies

Segment-level clarity is essential for strategic decision making because oncology markets are heterogeneous across modality, indication, channel, administration route, therapy line, mechanism, and formulation. The analysis disaggregates the landscape by drug type, distinguishing Biologics and Small Molecule approaches and recognizing the differing development, manufacturing, and regulatory footprints those modalities entail. It concurrently addresses indication diversity by covering Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, and Prostate Cancer to reflect variation in patient populations, standard-of-care backdrops, and clinical trial design imperatives.

Distribution channels receive dedicated attention with separate consideration of Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies to capture differences in procurement cycles, reimbursement navigation, and patient access pathways. The role of administration routes, categorized into Intravenous, Oral, and Subcutaneous delivery, informs patient experience, adherence considerations, and care setting requirements. Therapy line segmentation-First-Line, Second-Line, and Third-Line Plus-highlights differential clinical endpoints and pricing strategies appropriate to treatment positioning. Mechanism of action is examined across Chemotherapy, Immunotherapy, and Targeted Therapy, with immunotherapy further parsed into CAR-T Therapy and Checkpoint Inhibitors and targeted therapy further detailed into Monoclonal Antibodies and Tyrosine Kinase Inhibitors to reflect distinct development pathways and commercialization dynamics. Finally, formulation is considered across Liquid, Lyophilized Powder, and Tablet formats, recognizing that stability, cold-chain needs, and patient administration preferences materially affect supply chain design and adoption curves.

Regionally nuanced insights into regulatory, reimbursement, and access drivers across the Americas, Europe Middle East & Africa, and Asia Pacific markets

Regional dynamics exert powerful influence on regulatory timelines, reimbursement frameworks, and patient access pathways, so geographic nuance is central to any meaningful strategy. The analysis identifies distinctive patterns across the Americas, where diverse payer models and concentrated biopharma innovation hubs coexist with varied national procurement systems that affect pricing and distribution choices. In this context, commercialization strategies must adapt to heterogeneous formulary processes and physician practice patterns while leveraging large patient datasets to support value demonstration.

Europe, Middle East & Africa presents a complex mosaic of centralized regulatory influence alongside country-level reimbursement heterogeneity. Stakeholders operating across this region must balance centralized approvals with fragmented coverage decisions and be prepared to engage local health technology assessment bodies to secure access. Asia-Pacific markets display rapid adoption of innovative therapies in certain markets coupled with strong domestic manufacturing ambitions and distinctive regulatory pathways, which creates opportunities for partnership models, technology transfer agreements, and differentiated launch sequencing. Across all regions, companies must align clinical evidence, pricing tactics, and supply chain design to regional priorities and institutional capabilities.

How established pharmaceutical leaders and agile biotechnology firms are aligning portfolios, manufacturing, and diagnostic partnerships to drive oncology innovation

Leading biopharmaceutical companies continue to shape therapeutic direction through heavy investment in targeted modalities, immuno-oncology, and platform technologies that accelerate candidate discovery. Strategic portfolios now balance established chemistry expertise with biologics and cellular therapy capabilities, reflecting how multi-modality strategies de-risk pipelines and create synergies across development programs. Key players also invest in companion diagnostics and data-driven patient selection to enhance clinical outcomes and differentiate value propositions in price-sensitive conversations with payers.

Operationally, large integrated organizations are optimizing global manufacturing footprints to combine scale economics with regional responsiveness, deploying modular and single-use systems for biologics while expanding capabilities for final assembly and packaging close to major markets. At the same time, nimble specialized biotechs are advancing disruptive modalities and pursuing focused indications where rapid path to clinic and strategic partnerships can unlock value. Collaboration between incumbent firms and innovators - through licensing, co-development, and strategic acquisitions - remains a primary mechanism to accelerate access to novel mechanisms while distributing clinical and commercial risk across partners.

Practical strategic actions for industry leaders to synchronize evidence generation, supply resilience, diagnostic alignment, and access mechanisms for oncology therapies

Industry leaders should prioritize an actionable mix of scientific, commercial, and operational initiatives to maintain competitive advantage. First, integrate evidence generation plans that combine randomized controlled trials with real-world evidence strategies to support value narratives for payers and health systems. This approach strengthens reimbursement negotiations and accelerates uptake across treatment settings. Second, invest in supply chain flexibility by pursuing supplier diversification, modular manufacturing technologies, and inventory strategies that reduce the impact of external shocks and trade policy uncertainty.

Third, refine go-to-market models by aligning product launch sequencing with regional regulatory pathways and payer readiness, while building targeted engagement programs for key opinion leaders and multidisciplinary care teams. Fourth, develop diagnostic and biomarker programs in parallel with therapeutic development to ensure that patient selection supports favorable benefit-risk profiles and differentiated outcomes. Finally, pursue collaborative commercialization arrangements and risk-sharing agreements with payers and providers to facilitate access while sharing the financial responsibility for long-term outcomes.

Comprehensive mixed-methods research design integrating primary stakeholder input, regulatory and clinical evidence, supply chain mapping, and rigorous validation protocols

The research approach combines qualitative and quantitative methods to ensure robust, reproducible insights that support decision making. Primary research includes structured interviews with clinical investigators, payer representatives, hospital pharmacy directors, and manufacturing leaders to capture real-time perspectives on adoption barriers, procurement dynamics, and production constraints. Secondary research leverages regulatory filings, peer-reviewed literature, clinical trial registries, and publicly available health authority guidance to triangulate clinical pathways, safety profiles, and approval precedents.

Analytical methods encompass systematic mapping of supply chains, patent landscape reviews, and scenario analysis of policy and trade developments to stress-test strategic options. Data quality assurance is achieved through cross-validation of primary responses with documentary evidence and sensitivity analyses that identify key assumptions driving strategic conclusions. Throughout the methodology, ethical standards for data collection and confidentiality are maintained, and findings are presented with transparent caveats and reproducible documentation to support informed executive decision making.

Synthesis of key strategic imperatives highlighting the need for integrated execution, supply adaptability, and evidence driven access to deliver oncology innovations

In conclusion, oncology therapeutics are at an inflection point where scientific momentum must be matched by commercial agility and operational resilience. The maturation of targeted agents, immunotherapies, and advanced formulations offers new clinical pathways for patients, yet these opportunities come with increased complexity in evidence generation, manufacturing, and market access. Organizations that proactively align cross-functional resources-combining clinical development with diagnostic strategy, payer engagement, and supply chain adaptability-will be best positioned to translate innovation into sustained patient impact.

Looking forward, strategic success will depend on disciplined scenario planning, investments in flexible manufacturing and digital supply chain visibility, and collaborative approaches to demonstrate long-term value. By focusing on integrated execution and pragmatic risk mitigation, stakeholders can navigate regulatory heterogeneity, address tariff and trade uncertainties, and deliver therapies that improve outcomes while meeting the operational realities of healthcare systems worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Generic Oncology Drugs Market, by Drug Type

  • 8.1. Biologics
  • 8.2. Small Molecule

9. Generic Oncology Drugs Market, by Indication

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Leukemia
  • 9.4. Lung Cancer
  • 9.5. Lymphoma
  • 9.6. Prostate Cancer

10. Generic Oncology Drugs Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Generic Oncology Drugs Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral
  • 11.3. Subcutaneous

12. Generic Oncology Drugs Market, by Therapy Line

  • 12.1. First-Line
  • 12.2. Second-Line
  • 12.3. Third-Line Plus

13. Generic Oncology Drugs Market, by Mechanism Of Action

  • 13.1. Chemotherapy
  • 13.2. Immunotherapy
    • 13.2.1. CAR-T Therapy
    • 13.2.2. Checkpoint Inhibitors
  • 13.3. Targeted Therapy
    • 13.3.1. Monoclonal Antibodies
    • 13.3.2. Tyrosine Kinase Inhibitors

14. Generic Oncology Drugs Market, by Formulation

  • 14.1. Liquid
  • 14.2. Lyophilized Powder
  • 14.3. Tablet

15. Generic Oncology Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Generic Oncology Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Generic Oncology Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Generic Oncology Drugs Market

19. China Generic Oncology Drugs Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Accord Healthcare Ltd.
  • 20.6. Amneal Pharmaceuticals Inc.
  • 20.7. Aspen Pharmacare Holdings Ltd.
  • 20.8. Aurobindo Pharma Ltd.
  • 20.9. Biocon Limited
  • 20.10. Celltrion Healthcare Co., Ltd.
  • 20.11. Cipla Inc.
  • 20.12. Dr. Reddy's Laboratories Ltd.
  • 20.13. Fresenius Kabi AG
  • 20.14. Gedeon Richter Plc.
  • 20.15. Glenmark Pharmaceuticals Ltd.
  • 20.16. Hikma Pharmaceuticals Plc
  • 20.17. Intas Pharmaceuticals Ltd.
  • 20.18. KRKA d.d., Novo mesto
  • 20.19. Lupin Pharmaceuticals Inc.
  • 20.20. MSN Laboratories
  • 20.21. Sandoz Group AG
  • 20.22. Sawai Pharmaceutical Co., Ltd
  • 20.23. Shanghai Fosun Pharmaceutical Group Co., Ltd.
  • 20.24. STADA Arzneimittel AG
  • 20.25. Sun Pharmaceutical Industries Ltd.
  • 20.26. Teva Pharmaceutical Industries Ltd.
  • 20.27. Torrent Pharmaceuticals Ltd.
  • 20.28. Viatris Inc.
  • 20.29. Zydus Cadila Healthcare Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENERIC ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SECOND-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THIRD-LINE PLUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THIRD-LINE PLUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THIRD-LINE PLUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 191. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. GCC GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 214. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 221. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. G7 GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 230. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 231. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL GENERIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA GENERIC ONCOLOGY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)